Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

February marks the 75th anniversary of the first therapeutic dose of penicillin given to a patient in 1941 at Briscoe Ward, Radcliffe Infirmary.

Wingfield-Morris Orthopaedic Hospital in the 1940s. © Oxford University Hospital Foundation Trust
Wingfield-Morris Orthopaedic Hospital in the 1940s.

Read what part Oxford's orthopaedics played in the history of the 'wonder drug'.

In vivo trials at the Sir William Dunn School of Pathology

When Fleming published his famously serendipitous discovery of the antibacterial action of Penicillium notatum1, its therapeutic potential was largely ignored. It was in the late 1930s that researchers at the Dunn School of Pathology not only confirmed his findings but also started purification of the highly unstable substance.

In March 1940, Ernst Boris Chain asked his friend John Morrison Barnes to perform a first preliminary toxicity test on a lab animal. Dr. Barnes, who held the required license from the Home Office, had been a Nuffield Research Fellow in Orthopaedic Surgery and House Surgeon at the Wingfield-Morris Orthopaedic Hospital before joining Florey's department. Here, he conducted research and collaborated with the newly arrived Josep Trueta on work related to war injuries2.

Trueta recalls the incident in his biography: [...] A few weeks later Chain brought to the laboratory where Barnes and I were working some samples of a yellow liquid containing varying concentrations of penicillin. Barnes took some mice and injected them all with staphylococci and some with the penicillin serum. Eventually those mice which had been injected only with staphylococci died, while those which had also been inoculated with the new drug survived3.

This would later be described by Chain as 'the crucial day in the whole development of penicillin and the day on which everything became possible to us'4.

Further tests proved penicillin being active in vivo and findings were published in The Lancet5.

Clinical trials and the Wingfield-Morris Orthopaedic Hospital




Professor Florey and his co-workers in the Department of Pathology have discovered that one variety of a certain mold called penicillin [...] produces a most powerful substance intensely lethal to any organism that produce serious infection conditions. [...] Professor Florey has placed at our disposal a small quantity of the substance [...] for use in cases of severe infection. The evidence at present available suggests that it is a most valuable drug and it may perhaps prove effective in combating certain infections that have so far baffled us completely. - WMOH Annual Report, 1941

Preparative work was then undertaken to accumulate enough stable penicillin to permit trials on patients with normally fatal bacterial infections. Earlier treatment of septic wounds under Lady Florey's supervision directly applying gauze soaked in penicillin solution had failed to provide a clear proof of the efficacy of penicillin and it seemed likely that intravenous therapy would give clearer results.


In January 1941, Charles Fletcher from the Radcliffe Infirmary started to try out various routes of administration with a first test penicillin injection to a volunteer patient with breast cancer. Other than developing a rigor and temporary temperature rise there were no ill effects. This set the start and systematic penicillin treatment began on 12th February on a 43-year old patient from the septic ward (Case 1). The patient improved but unfortunately supplies exhausted after five days and he succumbed to the infection on 15 March.

The second patient was offered from the Wingfield by Gathorne Girdlestone, a 15-year old boy with a theatre acquired infection of a pinned epiphysiolysis (Case 2). Unresponsive to sulfonamides and blood transfusions, intravenous penicillin treatment started on 22nd February under Dr. Fletcher (100mg, 2-hourly, for 8 hours, then smaller dosage for 5 days). Despite of the short course and the small quantity given (total administration: 3.4g), the boy's condition improved and four weeks later he was fit enough to undergo surgery to remove the pin that caused the infection6, 7.

From this he recovered completely and, together with the four surviving members of the Oxford team that gave the world the 'wonder drug', he attended the 50th Anniversary celebrations at the Radcliffe Infirmary in 1991.

Article by

Ulrike BilgramUlrike Bilgram is currently working on a project focussing on the history of academic orthopaedics in Oxford and its relationship with orthopaedic care and training.
For details about the project visit the NDORMS History Project.




1. FLEMING, A. (1929). On the antibacterial action of cultures of a penicillium: with special reference to their use in isolation of B. influenzæ. British Journal of Experimental Pathology. 10.

2. TRUETA, J., & BARNES, J. M. (n.d.). The Rationale of Complete Immobilization in Treatment of Infected Wounds.

3. TRUETA, J. (1980). Trueta, surgeon in war and peace: the memoirs of Josep Trueta, M.D., F.R.C.S., D. Sc. London, V. Gollancz, p.149-150.

4. CLARK, R. W. (1985). The life of Ernst Chain: penicillin and beyond. New York, St. Martin's Press, p.47

5. CHAIN, E. B., & FLOREY, H. (1940). Penicillin as a chemotherapeutic agent. The Lancet. 238, 226-228.

6. ABRAHAM, E., CHAIN, E., FLETCHER, C., GARDNER, A., HEATLEY, N., JENNINGS, M., & FLOREY, H. (1941). Further observations on Penicillin. The Lancet. 238, 177-189. 7. LAWRIE, R. (1985). First clinical use of penicillin. BMJ. 290, 397-397.

7. LAWRIE, R. (1985). First clinical use of penicillin. BMJ. 290, 397-397.

Find out more

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators


Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).